Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

Bookmark and Share
Published: 13 Jun 2020
Views: 607
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

Dr Courtney DiNardo speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

She provides an overview of the trial, which is investigating enasidenib plus azacitidine versus azacitidine alone in patients with mutant-IDH2 newly diagnosed acute myeloid leukaemia (ND-AML).

Dr DiNardo outlines the design of this randomised phase II portion of the trial, and notes that this treatment combination significantly improved complete remission and overall response rates in these patients.

She also presents the toxicity profile of this novel combination, which was generally well-tolerated in this population of patients.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.